Lv41
740 积分 2025-10-16 加入
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer
2小时前
求助中
An intercostal artery aneurysm rupture in a patient with neurofibromatosis type 1-associated gastrointestinal stromal tumor during sunitinib therapy
27天前
已完结
Midostaurin-Associated acute pancreatitis
1个月前
已完结
The optimal choice for maintenance therapy in ovarian cancer with HR-proficient (HRp)/unknown status: A comparison of Bevacizumab and Niraparib
1个月前
已完结
Profiling the immune repertoire in a phase II trial of niraparib and dostarlimab in recurrent or persistent uterine serous carcinomas
1个月前
已关闭
Patient-reported outcomes from the final analysis of the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: Results from the homologous recombination-deficient (HRd) and -proficient (HRp) populations
1个月前
已完结
Risk Factors for Niraparib-induced Severe Anemia in Japanese Patients With Ovarian Cancer: A Multicenter Study
1个月前
已完结
Real-world safety profile and clinical management of patients (pts) with epithelial ovarian cancer (EOC) who received first-line maintenance (1LM) niraparib therapy: Final results from the 1NSPIRE chart review study
2个月前
已完结
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)
2个月前
已完结
皖公网安备34019202002308
